When did Louis Pasteur present his memoir on the discovery of molecular chirality to the Académie des sciences? Analysis of a discrepancy

Louis Pasteur presented his historic memoir on the discovery of molecular chirality to the Académie des sciences in Paris on May 22nd, 1848. The literature, however, nearly completely ignores this date, widely claiming instead May 15th, 1848, which first surfaced in 1922 in Pasteur's collected works edited by his grandson Louis Pasteur Vallery-Radot. On May 21st, 1848, i.e., one day before Pasteur's presentation in Paris, his mother died in Arbois, eastern France. Informed at an unknown point in time that she was "very ill," Pasteur left for Arbois only after his presentation. Biographies of Pasteur by his son-in-law René Vallery-Radot or the grandson, and Pasteur's collected correspondence edited by the grandson are incomprehensibly laconic or silent about the historic presentation. While no definite conclusions are possible, the evidence strongly suggests a deliberate alteration of the record by the biographer relatives, presumably for fear of adverse public judgment of Pasteur for a real or perceived insensitivity to a grave family medical emergency. Such fear would have been in accord with their hagiographic portrayal of Pasteur, and the findings raise questions concerning the extent of their zeal in protecting his "demigod" image. Universal recognition of the true date of Pasteur's announcement of molecular chirality is long overdue.     

Pasteur, oxygen and the anaerobes revisited

As a biochemist, Louis Pasteur focused on fermentation, demonstrating that it was a vital process. In 1860, he discovered anaerobic life and the strict anaerobes, particularly those responsible for butyric fermentation. Then, in spite of his lack of medical background, Pasteur turned to investigating the role of bacteria in human and animal diseases. In 1877, Pasteur and Joubert described for the first time a pathogenic anaerobe, the 'septic vibrio' (now Clostridium septicum). Not only was the bacterium cultivated, but the disease symptoms described and the disease experimentally reproduced. Pasteur also described what are now known as mixed anaerobic infections. A historical review of Pasteur's work is made in the light of our present knowledge of this field.     

Role of phosphate in the regulation of the Pasteur effect in Saccharomyces cerevisiae

The occurrence of the Pasteur effect in Saccharomyces cerevisiae in several conditions has been examined. In these conditions measurements of a series of metabolites potentially involved in the regulation of the effect were performed. These included, among others, adenine nucleotides, citrate, fructose 2,6-bisphosphate and phosphate. Only phosphate changed in a consistent way, increasing in anaerobiosis when the Pasteur effect occurred. It is concluded that, with the available data, only phosphate may be considered as a regulator of the Pasteur effect in this microorganism.     

The Pasteur effect in rat jejunum and the influence of nematode infections.

1. The Pasteur effect was shown after 15 min but not after 30 min incubation of jejunal rings from normal rats. 2. During 15-30 min incubation, the rate of anaerobic lactate production decreased, while aerobic lactate production remained unchanged. Thus oxygen was necessary to maintain the functional integrity of the tissue during this period. 3. After infection with either Nematospiroides dubius or Nippostrongylus brasiliensis, the Pasteur effect could not usually be shown, mainly due to a reduced rate of anaerobic lactate production. 4. The possible relationship of the loss of the Pasteur effect to the immune response is discussed.     

Appropriation and commercialization of the Pasteur anthrax vaccine

Whereas Pasteur patented the biotechnological processes that he invented between 1857 and 1873 in the agro-food domain, he did not file any patents on the artificial vaccine preparation processes that he subsequently developed. This absence of patents can probably be explained by the 1844 patent law in France that established the non-patentable status of pharmaceutical preparations and remedies, including those for use in veterinary medicine. Despite the absence of patents, the commercial exploitation of the anthrax vaccine in the 1880s and 1890s led to a technical and commercial monopoly by Pasteur's laboratory as well as the founding of a commercial company to diffuse the vaccine abroad. Pasteur repeatedly refused to transfer his know-how and anthrax vaccine production methods to foreign laboratories, on the grounds that he wished to control the quality of the vaccines produced. Indeed, it was relatively difficult to transfer a method that was not yet perfectly stabilized in the early 1880s. Pasteur also wanted to maintain the monopoly of his commercial company and to increase the profits from vaccine sales so that the Institut Pasteur could be financially independent. The 'Pasteur anthrax vaccine' operating licences are described and analysed in detail in this article.     

Mathematical model for carbohydrate energy metabolism. Mechanism of the Pasteur effect

The simple mathematical model based on the stoichiometric structure of carbohydrate metabolism and the only allosteric regulation presented, i. e. activation of phosphofructokinase by AMP, was used to study the mechanism of the Pasteur effect, e. g. interrelationship of glycolysis, the Krebs cycle and H-transporting shuttles at varying rates of oxidative phosphorylation and ATPase load. It was shown that the mechanism of the Pasteur effect is based on the presence of two negative feed-back mechanisms in carbohydrate metabolism, namely by the level of ATP in glycolysis and by the level of mitochondrial NADH in the Krebs cycle and H-transporting shuttles. It was also shown that the value and sign of the Pasteur effect depend on the level of ATPase load. The role of this phenomenon in stabilization of ATP in the cell is discussed. The effects of changes in the allosteric properties of phosphofructokinase and low activity of H-transporting shuttles on the Pasteur effect was studied. It was shown that the low values of the pasteur effect in tumour tissues are mainly determined by an insufficient activity of oxidative phosphorylation.     

The Pasteur effect and catabolite repression in an oxidative yeast,Kluyveromyces lactis

The presence of the Pasteur effect in Kluyveromyces lactis grown in glucose was shown by azide-stimulated glucose fermentation. Extracts from these cells contained ATP-sensitive phosphofructokinase activity. Cells grown on succinate oxidized glucose slowly at first without azide-stimulated rates of fermentation. Phosphofructokinase in these cells was ATP-insensitive. The activity of NAD+-isocitrate dehydrogenase in cell extracts did not require AMP activation. These results suggested the presence of a Pasteur effect in glucose-grown but not in succinate-grown K. lactis, mediated by (a) ATP inhibition of phosphofructokinase (b) possibly via feedback control of glucose transport, but not by AMP activation of isocitrate dehydrogenase. Azide inhibition of the Pasteur effect during growth of the cells did not lead to catabolite repression of respiratory activity. The results therefore suggest that the Pasteur effect does not inhibit the development of a Crabtree effect in oxidative yeasts.     

Energetic irrelevance of aerobiosis for S. cerevisiae growing on sugars

Summary The net benefit that Saccharomyces cerevisiae obtains from aerobiosis as compared to anaerobiosis has been studied. For this purpose yeasts with different respiratory capacities have been obtained by growing them in batch cultures on different substrates. Even with sugars with low catabolite repression effect, as is the case of galactose, aerobiosis increased the growth rate and the growth yield by less than two-fold. These variations, which are much lower than the expected considering the actual oxygen utilization, indicate that either the amount of ATP produced in respiration is much lower than the theoretically expected or a much greater expenditure of ATP occurs in aerobic than in anaerobic growth. The results show that S. cerevisiae obtains only a slight benefit from aerobiosis when growing on sugars at the relatively high concentration prevailing in its natural habitats.The inhibition of sugar consumption rate by aerobiosis (Pasteur effect) has also been studied, Pasteur effect was almost unnoticeable during growth on any tested sugar and very low during ammonia starvation. These results contrast with the general belief that Pasteur effect is a quantitatively important phenomenon in yeast. It is concluded that the relevant observations of Louis Pasteur have little relationship with the phenomenon that bears his name.     

Association of the encapsulation of Bacillus anthracis with a 60 megadalton plasmid

Virulent typical strains (Shikan, Morioka, Shizuoka) and Pasteur vaccine strains (no. 1, no. 2-H, no. 2-17JB) of Bacillus anthracis harboured two plasmid species with molecular masses of 110 MDal and 60 MDal. All of the 110 MDal plasmids isolated from the various strains showed indistinguishable patterns of digestion with restriction endonucleases. All the 60 MDal plasmids were also indistinguishable. Strain Davis, which is encapsulated but is asporogenous and avirulent, harboured only the 60 MDal plasmid while three non-encapsulated vaccine strains (34F2, Smith, Mukteswer) harboured only the 110 MDal plasmid. Four non-encapsulated variant strains obtained from the encapsulated strains Shikan, Pasteur no. 1, Pasteur no. 2-17JB and Davis had lost the 60 MDal plasmid, suggesting that encapsulation of B. anthracis may be associated with the 60 MDal plasmid.     

The heuristic function of 'error' in the scientific methodology of Louis Pasteur: the case of the silkworm diseases

With the aid of the Cahiers de laboratoire, the Correspondence and, of course, the Oeuvre de Pasteur, this work reconstructs the extraordinary scientific undertakings of the great French scientist in his study of silkworm diseases. The focus of this study consists in the attempt to explain the initial perplexing behaviour of Pasteur, even in the presence of correct interpretations regarding the causes of these diseases (cfr. the results obtained by Béchamp); for a good three years he insisted on maintaining that the aetiology of silkworm diseases could not be attributed to pathogenetic germs from outside. And this was in spite of the fact that previously (through fermentation and spontaneous generation) he had been able to demonstrate the importance of microorganisms in biological processes. Finally it is intended to highlight the extraordinary methodological depth of that initial 'error', which was capable of paving the way for the future conquests of Pasteur in the field of aetiology and the prevention of infectious diseases.     

From the creation of the Veterinary Schools to the evolution of the notion of contagion in the 19th and 20th centuries

The creation of the Veterinary Schools in the 18th century would reveal a plethora of scientists, some of whom would be the precursors of Pasteur, some rivals, others followers collaborators or friends of the Master. Among the precursors let us name Chabbert, Huzard, Girard, Delafond, Renault, Toussaint, Galtier ; among the rivals: Chauveau, Arloing, Cornevin and Thomas; among the followers, collaborators or friends of Pasteur: Bouley, at first a resolute spontaneist, then the most fervent in defense of Pasteur (President of the Academy of Medicine and of the Academy of Sciences) and Nocard, Director of the School in Alfort, an important collaborator of Pasteur. Later, there was Leclainche, who created the International Office of Epizootics, and who was President of the Academy of Sciences; Guérin, who with Calmette developed the BCG vaccination; Ramon, the father of anatoxins (vaccines against diphtheria, and tetanus, combined vaccines, adjuvants to immunity). Thus, the creation of the Veterinary Schools contributed not only to the evolution of the notion of contagion, to the amelioration of animal health and the economics of agricultural production, but also to serious advances in human care, and to the protection of public health.     

Polymorphism of cytotoxic T-lymphocyte clones that recognize a defined nine-amino-acid immunodominant domain of lymphocytic choriomeningitis virus glycoprotein

To assess the heterogeneity of cytotoxic T lymphocytes (CTLs) directed against viral epitopes, we studied six class I major histocompatibility complex-restricted (H-2Db) CTL clones that recognize the same 9-amino-acid immunodominant epitope, amino acids 278 to 286 from envelope glycoprotein 2 (GP2) of lymphocytic choriomeningitis virus (LCMV). Using Southern blot analysis of beta-chain rearrangements, we found that each clone has a unique restriction pattern, providing evidence of the independent derivation of the clones and suggesting that the clones express different beta-chain sequences for their T-cell receptor. All these clones killed syngeneic target cells infected with strain Armstrong or WE of LCMV; however, two of the six clones failed to recognize target cells infected with the Pasteur strain of LCMV. Sequence analysis of LCMV Armstrong, WE, and Pasteur GP in the region of amino acids 272 to 293 demonstrated a single-amino-acid substitution at amino acid 278 in the region of the defined epitope in the Pasteur strain. Interestingly, one of the two CTL clones that failed to lyse LCMV Pasteur-infected target cells nevertheless efficiently and specifically killed uninfected target cells coated with the appropriate LCMV Pasteur peptide, while the other clone failed to do so. This indicated a dichotomy between processing of the synthesized protein initiated by infection and a peptide exogenously applied. Dose-response studies utilizing several peptides with substitutions in GP amino acid 278 indicate that CTL recognition occurs at the level of a single amino acid and suggest that this difference is likely recognized at the level of the T-cell receptor.     

Strain-specific differences in the genetic control of two closely related mycobacteria

The host response to mycobacterial infection depends on host and pathogen genetic factors. Recent studies in human populations suggest a strain specific genetic control of tuberculosis. To test for mycobacterial-strain specific genetic control of susceptibility to infection under highly controlled experimental conditions, we performed a comparative genetic analysis using the A/J- and C57BL/6J-derived recombinant congenic (RC) mouse panel infected with the Russia and Pasteur strains of Mycobacterium bovis Bacille Calmette Guérin (BCG). Bacillary counts in the lung and spleen at weeks 1 and 6 post infection were used as a measure of susceptibility. By performing genome-wide linkage analyses of loci that impact on tissue-specific bacillary burden, we were able to show the importance of correcting for strain background effects in the RC panel. When linkage analysis was adjusted on strain background, we detected a single locus on chromosome 11 that impacted on pulmonary counts of BCG Russia but not Pasteur. The same locus also controlled the splenic counts of BCG Russia but not Pasteur. By contrast, a locus on chromosome 1 which was indistinguishable from Nramp1 impacted on splenic bacillary counts of both BCG Russia and Pasteur. Additionally, dependent upon BCG strain, tissue and time post infection, we detected 9 distinct loci associated with bacillary counts. Hence, the ensemble of genetic loci impacting on BCG infection revealed a highly dynamic picture of genetic control that reflected both the course of infection and the infecting strain. This high degree of adaptation of host genetics to strain-specific pathogenesis is expected to provide a suitable framework for the selection of specific host-mycobacteria combinations during co-evolution of mycobacteria with humans.     

The 'experimental stable' of the BCG vaccine: safety, efficacy, proof, and standards, 1921-1933

The anti-tuberculosis BCG (Bacille Calmette-Guérin) vaccine was conceived and developed between 1905 and 1921 at Pasteur Institutes in France. Between 1921 and A. Calmette's death in 1933, the vaccine went through a first period of national and international production and distribution for its use in humans. In France these activities were exclusively carried out by Calmette and his collaborators at the Pasteur Institute in Paris. Initially improvised production in a small room in the cellar gave way in 1931 to the construction of the spacious and magnificent 'New laboratories for research on tuberculosis and the preparation of the BCG' within the premises of the Pasteur Institute. Presentation and image-building of the vaccine in France insisted on the fact that the BCG was not a commercial specialty but distributed free of charge. The technical monopoly of its production nevertheless lay with the Paris Pasteur Institute and standardization of scientific proof of safety, efficacy and stability was dominated by that Institute in France. In contrast, the international production and distribution of the vaccine was entrusted and transferred, free of charge, to trustworthy laboratories outside France. Multiplication of producers and users led to an increased need for standardization. For this process the analysis distinguishes between the standardization of scientific proof concerning safety, efficacy and stability of the vaccine and standardization of its medical uses. Whereas standardization was rather successful in the inter-war period in France, the international efforts remained rather unsuccessful. Only after world war II under Scandinavian leadership and in the context of mass vaccination programs supported by the WHO and UNICEF was the international standardization effectively implemented and succeeded at least to some extend.     

Molecular characterization of Streptococcus equi subspecies equi isolated from an Ethiopian camel by ribotyping and PCR-ribotyping.

The aim of this study was to characterize a S. equi subspecies equi strain isolated from an Ethiopian camel by different molecular techniques (Ribotyping and PCR-Ribotyping). We compared the results obtained with those generated from two strains of the Pasteur Collection. The ribotyping showed the highest power of differentiation, distinguishing between the strains analyzed, whereas PCR-Ribotyping was able only to differentiate the camel isolate but not the strains from the Pasteur Collection. The application of this technique will be very useful to establish a clonal relationship among equine and camelids strains and help the prevention and cure of the equine and camel pathology.     

Duclaux,Chamberland, Roux,Grancher, and Metchnikoff: the five musketeers of Louis Pasteur

The Institut Pasteur was created thanks to worldwide generosity with the aim to welcome and treat rabies patients, to provide a place for scientific research and to offer new teaching programs in microbiology. Louis Pasteur invited his main collaborators, who had accompanied him during his previous investigations at École Normale Supérieure, to join him in his new institute. They contributed to the principle discoveries of Pasteur, such as the fight against spontaneous generation, the identification of the ferments of putrefaction, the fight against the silk worm disease, the research on wine and beer, and the set-up of the first vaccines against avian cholera, anthrax, swine erysipelas and rabies. There were two scientists, Émile Duclaux and Charles Chamberland, and two medical doctors, Émile Roux, and Joseph Grancher. In addition, two Russian scientists were invited to join the Institute and to head a research laboratory, Élie Metchnikoff and Nikolaï Gamaleïa, the later will finally never join the institute.     

The ‘experimental stable’ of the BCG vaccine: safety, efficacy, proof, and standards, 1921–1933

The anti-tuberculosis BCG (Bacille Calmette-Guérin) vaccine was conceived and developed between 1905 and 1921 at Pasteur Institutes in France. Between 1921 and A. Calmette’s death in 1933, the vaccine went through a first period of national and international production and distribution for its use in humans. In France these activities were exclusively carried out by Calmette and his collaborators at the Pasteur Institute in Paris. Initially improvised production in a small room in the cellar gave way in 1931 to the construction of the spacious and magnificent ‘New laboratories for research on tuberculosis and the preparation of the BCG’ within the premises of the Pasteur Institute. Presentation and image-building of the vaccine in France insisted on the fact that the BCG was not a commercial specialty but distributed free of charge. The technical monopoly of its production nevertheless lay with the Paris Pasteur Institute and standardization of scientific proof of safety, efficacy and stability was dominated by that Institute in France. In contrast, the international production and distribution of the vaccine was entrusted and transferred, free of charge, to trustworthy laboratories outside France. Multiplication of producers and users led to an increased need for standardization. For this process the analysis distinguishes between the standardization of scientific proof concerning safety, efficacy and stability of the vaccine and standardization of its medical uses. Whereas standardization was rather successful in the inter-war period in France, the international efforts remained rather unsuccessful. Only after world war II under Scandinavian leadership and in the context of mass vaccination programs supported by the WHO and UNICEF was the international standardization effectively implemented and succeeded at least to some extend.     

Disappearance of Phosphorylation Activity of Nucleotides from the Mitochondria-rich Cells of an Yeast,Hansenula jadinii; a Modified Pasteur Effect

An yeast, Hansenula jadinii, which was one of the best producers of CDP-choline on our system, lost its activity when cultured in jar fermenter. This phenomenon was also reproduced in flasks. Cells cultured aerobically in the medium containing 1 % of glucose (A-cells) could not phosphorylate nucleotides although development of mitochondria was observed, whereas cells cultured less aerobically in the medium containing 5% of glucose (D-cells) could phosphorylate CMP to CTP and finally produce CDP-choline although they had only poor mitochondria. Further study revealed that the A-cells were unstable in hexokinase activity, although they had the dense cytosol, whereas the D-cells remained stable, and they had many round particles. Glycolytic activity was about 4 times stronger in the D-cells than in the A-cells. The phenomenon that respiration (development of mitochondria) suppressed fermentation (glycolysis) has been known as the Pasteur effect. However, in our system, phosphofructokinase, the primary key enzyme of the Pasteur effect, was active in the A-cells. Therefore, our phenomenon seemed to be a modified Pasteur effect.     

Glycolysis and respiration in yeasts. The Pasteur effect studied by mass spectrometry.

Simultaneous and continuous measurements of changes in CO2 and O2 concentrations in glucose-metabolizing yeast suspensions by mass spectrometry enabled a study of the Pasteur effect (aerobic inhibition of glycolysis) in Saccharomyces uvarum and Schizosaccharomyces pombe. A different control mechanism operates in Candida utilis to give a damped oscillation after the anaerobic-aerobic transition. The apparent Km values for respiration of the three yeasts were in the range 1.3-1.8 microM-O2. The apparent Km values for O2 of the Pasteur effect were 5 and 13 microM for catabolite-repressed and derepressed S. uvarum respectively and 7 microM for Sch. pombe. These results are discussed with respect to currently accepted mechanisms for the control of glycolysis.     

Comparison of various BCG preparations in the EORTC — ICIG experimental screening for systemic immunity adjuvants applicable to cancer immunotherapy

Summary Nine lyophilized, five frozen, and one fresh BCG preparation from various sources were tested for their activity as adjuvants of systemic immunity in mice. Using three tests, the IgM response to sheep red blood cells, immunoprophylaxis of L1210 leukemia, and immunoprophylaxis of Lewis tumor, results consistent with both immunostimulation and immunodepression were observed, varying as a function of the BCG strain, its storage conditions, and the assay used. Only fresh Pasteur strain BCG was effective in all three tests; its activity was modified by lyophilization and by freezing. Possible reasons for the superiority of fresh Pasteur BCG as an adjuvant are discussed.European Organization for Research and Treatment of CancerInstitut de Cancérologie et d'Immunogénétique